The CD3+/FOXP3+ cell ratio [88] and the CD8+/FOXP3+ cell ratio [89] are both predictive markers for disease-free survival time and overall survival time in patients with CRC, supporting the down-modulatory role of Treg in the presence of protective cytotoxic T-cells. This evidence concerns the gene CD8A and colorectal carcinoma.